A survival analysis of the clinical ovarian cancer database indicated a correlation between higher FBXO6 expression and the overall survival in ovarian cancer patients at advanced stages (stage 2 + 3, stage 3 + 4, or stage 2 + 3 + 4) were observed (Fig. 5B). The gene discussed is FBXO6; the disease is ovarian cancer.